NCE-1 Intelligence & Market Opportunity

Welireg

Belzutifan

Anticancer

Oral Tablet

Approval Date

13-Aug-21

NCE-1 Date

13-Aug-25

NCE Date

13-Aug-26

Commercial snapshot

Market performance & projections

Revenue ($M)

716

CAGR (%)

0.2665

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

937

2027

1239

2028

1586

2029

1842

2030

1910

2031

2080

2032

2235

Molecule profile

Details & specifications

Molecule

Belzutifan

Innovator

MERCK SHARP & DOHME LLC

Dosage Form

Oral Tablet

Strength

40 mg

Therapeutic Category

Anticancer

Usage

To treat von Hippel-Lindau disease under certain conditions

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.